ClinicalTrials.gg
RecruitingNCT07610564EmpaSoundUpdated Nov 16, 2026

A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

A Phase 1 interventional study of Empasiprubart IV in Multifocal Motor Neuropathy (MMN), sponsored by argenx. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by argenx · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 16, 2026First site in United States1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects.

The study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months.

The total study duration for each participant will be approximately 29 months.

More information can be found here: clinicaltrials.argenx.com/empasound

02

Conditions studied

  • Multifocal Motor Neuropathy (MMN)
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years old
  • Diagnosed with MMN
  • Has an MMN-RODS centile score of ≤90
  • Has confirmed nerve thickening in at least 1 nerve per ultrasound measurement

Exclusion criteria

Exclusion Criteria:

  • Besides the indication under study, known disease or any medical condition that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of MMN or puts the participant at undue risk.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Empasiprubart IV

    Participants receive empasiprubart IV

    Biological: Empasiprubart IV

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in nerve CSA at week 24 as measured by ultrasound imaging of the median nerve and brachial plexus (individual nerves and average sum score)

    CSA : cross-sectional area

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Change from baseline in GS in both hands over time

    The grip strength (GS) will be measured using a vigorimeter

    Time frame: Up to 48 weeks

  2. Change from baseline in MMN-RODS over time

    The MMN Rasch-Built Overall Disability Scale (MMN-RODS) is a disease-specific patient-reported outcome instrument that captures activity limitations in patients with MMN. The total raw score will be transformed to a centile score, ranging from 0 (worst outcome) to 100 (best outcome)

    Time frame: Up to 48 weeks

  3. Change from baseline in mMRC-14 sum score over time

    The modified Medical Research Council (mMRC)-14 is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body

    Time frame: Up to 48 weeks

  4. Percentage change from baseline in time to complete the 9-HPT with both hands over time

    The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand).

    Time frame: Up to 48 weeks

  5. Change from baseline in nerve CSA over time as measured by ultrasound imaging of the median nerve and brachial plexus

    CSA : cross-sectional area

    Time frame: Up to 48 weeks

  6. Serum concentrations of empasiprubart over time

    Time frame: Up to 60 weeks

  7. Percentage change from baseline in free C2 and total C2 over time

    C2 : complement component 2

    Time frame: Up to 60 weeks

  8. Incidence of AEs and AESIs

    AE : adverse event ; AESI : adverse event of special interest

    Time frame: Up to 60 weeks

  9. Incidence of SAEs

    SAE : Serious adverse event

    Time frame: Up to 60 weeks

07

Study locations

5 of 5 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 28, 2026
StartActual
Jul 27, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Apr 1, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • Yale University School of Medicine · New Haven, United States
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added — first site in United States
    Show site
    • Yale University School of Medicine · New Haven, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07610564
Lead sponsor
argenx
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Jul 27, 2026
Primary completion
Feb 1, 2028 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empasiprubart

Start the discussion